You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

hormone receptor positive, HER2 negative

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in New Brunswick (U-13C-glucose)

Not yet recruiting
  • Breast Cancer
  • New Brunswick, New Jersey
  • +1 more
Feb 16, 2023

Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Fulvestrant plus AI plus ribociclib
  • AI plus ribociclib
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Apr 16, 2023

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer Trial (Ribociclib, Fulvestrant,

Not yet recruiting
  • Locoregional Recurrence
  • +2 more
  • (no location specified)
Jul 18, 2022

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 1, 2023

    Real-World Data on First-line Treatment of Hormone

    Recruiting
    • Breast Cancer
      • Porto Alegre, Rio Grande Do Sul, Brazil
        CPO
      Aug 15, 2022

      Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial

      Not yet recruiting
      • Anatomic Stage I Breast Cancer AJCC v8
      • +5 more
      • Atlanta, Georgia
        Emory University Hospital/Winship Cancer Institute
      Jul 14, 2022

      Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Breast Carcinoma Trial in

      Withdrawn
      • Anatomic Stage IV Breast Cancer AJCC v8
      • +4 more
      • Bintrafusp Alfa
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Sep 2, 2022

      Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Alpelisib, Tamoxifen, Infigratinib)

      Not yet recruiting
      • Breast Cancer
      • +2 more
      • Stanford, California
        Stanford University
      Nov 16, 2022

      Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer Trial in

      Recruiting
      • Hormone Receptor Positive Breast Carcinoma
      • +2 more
      • Chicago, Illinois
      • +2 more
      Jul 1, 2022

      Advanced or Metastatic Breast Cancer Trial (PF-07220060, Fulvestrant, Everolimus)

      Not yet recruiting
      • Advanced or Metastatic Breast Cancer
      • (no location specified)
      Oct 24, 2023

      Breast Cancer Stage II Trial in Xi'an (Anlotinib)

      Recruiting
      • Breast Cancer Stage II
      • Xi'an, Shannxi Province, China
        Xijing Hospital Affiliated to Air Force Military Medical Univers
      Sep 25, 2022

      Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

      Active, not recruiting
      • Metastatic Breast Cancer
      • Hospitalet de Llobregat, Barcelona, Spain
      • +6 more
      Jan 23, 2023

      Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)

      Active, not recruiting
      • Breast Cancer
      • Guangzhou, Guangdong, China
        State Key Laboratory of Oncology in South China, Sun Yat-sen Uni
      Jan 27, 2023

      Breast Cancer Trial (Inavolisib, Fulvestrant, Alpelisib)

      Not yet recruiting
      • Breast Cancer
      • (no location specified)
      Jan 30, 2023

      Breast Adenocarcinoma, Invasive Breast Carcinoma, Resectable Breast Carcinoma Trial in Jacksonville (Biospecimen Collection,

      Recruiting
      • Breast Adenocarcinoma
      • +2 more
      • Jacksonville, Florida
        Mayo Clinic in Florida
      Jan 4, 2023

      Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Boston

      Not yet recruiting
      • Breast Cancer
      • +2 more
      • Boston, Massachusetts
      • +2 more
      Nov 3, 2022

      Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Houston (Radiation Therapy, Therapeutic

      Active, not recruiting
      • Estrogen Receptor Positive
      • +3 more
      • Radiation Therapy
      • Therapeutic Conventional Surgery
      • Houston, Texas
        M D Anderson Cancer Center
      Jun 14, 2022

      Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer Trial

      Not yet recruiting
      • Hormone Receptor-positive Breast Cancer
      • +2 more
      • Nashville, Tennessee
        Sarah Cannon Research Institute
      Oct 5, 2022

      Brain Metastases, HR+ Metastatic Breast Cancer Trial in Tampa (Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy)

      Recruiting
      • Brain Metastases
      • HR+ Metastatic Breast Cancer
      • Stereotactic Radiosurgery (SRS)
      • +2 more
      • Tampa, Florida
        Moffitt Cancer Center
      Nov 1, 2022

      Invasive Breast Cancer Trial in Milwaukee (Cemiplimab, Paclitaxel, Carboplatin (not mandatory))

      Recruiting
      • Invasive Breast Cancer
      • Milwaukee, Wisconsin
        Froedtert Hospital & Medical College of Wisconsin
      Apr 1, 2022

      Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma Trial in Washington, Baltimore, Hackensack

      Active, not recruiting
      • Breast Cancer
      • +2 more
      • Washington, District of Columbia
      • +4 more
      Jan 31, 2023

      Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)

      Recruiting
      • Locally Advanced Breast Cancer
      • Hormone Receptor Positiveļ¼ŒHER2-negative Breast Cancer
      • Jinan, Shandong, China
        Breast Cancer Center, Shandong Cancer Hospital and Institute
      Apr 11, 2023

      Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer Trial in Singapore (Oral lenvatinib + Intravenous (IV)

      Not yet recruiting
      • Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
      • Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
      • Singapore, Singapore
        National Cancer Centre Singapore
      Oct 13, 2022